Osimertinib
Treatment for Tracheal Bronchus And Lung Cancer
Typical Dosage: 80 mg orally once daily
Effectiveness
90%
Safety Score
32%
Clinical Trials
300
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
32
DangerousModerateSafe
Treatment Details
Dosage Range
80 mg orally once daily
Time to Effect
6-8 weeks
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$185,000
Monitoring:$7,000
Side Effect Mgmt:$5,000
Total Annual:$197,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$170,000/QALY
QALYs Gained
0.81
Outcome-Based Costs
Cost per Responder
$303,077
Cost per Remission
$6,566,667
Comparison vs Erlotinib or Gefitinib
Cost Difference
+$85,000/year
More expensive
QALY Difference
+0.81 QALYs
Better outcomes
Dominance
No dominance
Osimertinib Outcomes
for Tracheal Bronchus And Lung Cancer
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+65%
Remission Rate
+3%
Common Side Effects
Diarrhea
+50%
Rash
+40%
Dry skin
+30%
Nail toxicity
+30%
Fatigue
+30%
Interstitial Lung Disease
+4%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov